Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.
Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.
Learn more at https://www.biosplice.com
Company Details
- Employees
- 32
- Address
- 9360 Towne Centre Dr., San Diego,ca 92121,united States
- Industry
- Biotechnology
- Website
- http://www.biosplice.com
- HQ
- San Diego, CA
Biosplice Therapeutics Questions
Biosplice Therapeutics's website is http://www.biosplice.com
Biosplice Therapeutics's LinkedIn profile is https://www.linkedin.com/company/biospliceinc
Biosplice Therapeutics has
32 employees.
View email and phone details for 32
employees at Biosplice Therapeutics.
Biosplice Therapeutics's industry is
Biotechnology
Biosplice Therapeutics's top competitors are
Calico Life Sciences,
Tessera Therapeutics,
Hubx,
Tempus Ai,
Elevatebio,
Urla Şarapçılık,
Veloxia,
Crinetics Pharmaceuticals,
The Carolan Group,
Poseida Therapeutics, Inc..
Biosplice Therapeutics's categories are Biotechnology
